Ethical Dilemma with Stakeholders
You're the CEO of a pharmaceutical company. Your best-selling drug ($2B annual revenue, used by 4 million patients for chronic pain) has…
CEO’s 48-Hour Action Plan Context: I’ve just learned that our flagship chronic pain drug has a rare but serious liver failure risk (1 in 8,000 patients over 5 years), previously unknown. I have 48 hours until the board meeting and 72 hours until the earnings call.Read the full answer
As CEO, I would not wait six months and I would not let the board delay disclosure while patients remain exposed to an unreported serious risk. I would treat this as a patient-safety, regulatory, legal, and trust crisis—not merely a financial-risk issue. My guiding decisions would be: Patient safety comes first.Read the full answer